Nov 20, 2025 8:00am EST Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Nov 17, 2025 8:05am EST Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Sep 04, 2025 8:00am EDT Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Aug 19, 2025 8:00am EDT Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Aug 13, 2025 4:15pm EDT Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Jul 31, 2025 8:00am EDT Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Jul 16, 2025 8:00am EDT Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Jun 24, 2025 8:00am EDT Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2